Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18483425 | 1.00 | BACE1 (0.34) | BACE1CXCR2LIPELPLLIPG | |
| SCHEMBL16339641 | 0.87 | BACE1 (0.39) | BACE1CXCR2LIPELPLLIPG | |
| SCHEMBL19513476 | 0.80 | CXCR2 (0.40) | CXCR2LPLLIPG | |
| SCHEMBL31302813 | 0.78 | MGMT (0.30) | — | |
| SCHEMBL20237129 | 0.77 | LPL (0.33) | CXCR2LPLLIPGJAK2BTK | |
| SCHEMBL21751380 | 0.77 | LPL (0.36) | CXCR2LIPELPLLIPGJAK2 | |
| SCHEMBL16009606 | 0.77 | BACE1 (0.34) | BACE1LPLLIPG | |
| SCHEMBL31518114 | 0.77 | EGFR (0.31) | LPLLIPG | |
| SCHEMBL106623 | 0.77 | LPL (0.30) | LPLLIPG | |
| SCHEMBL24630498 | 0.77 | LPL (0.46) | LPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396514-B2 | Substituted guanidine compounds | UBE CORPORATION | 2022-07-26 | — | — | US | disclosed |
| CN-110114350-B | Substituted guanidine compounds | 宇部兴产株式会社 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396514-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | BACE1 3323/4885CXCR2 766/4885LIPE 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.